POPULAR SECTIONS

TREATMENT REGIMENS DRUG INFO MEDICAL CALCULATORS PUBLISHERS ALLIANCE VIDEOS CME

Subset of Colorectal Cancer Linked with Obesity, Physical Activity

Share this article:
Obesity, Physical Activity Linked to Risk in Subset of Colorectal CA
Obesity, Physical Activity Linked to Risk in Subset of Colorectal CA

(HealthDay News) -- Obesity and physical inactivity are associated with a higher risk of WNT/β-catenin (CTNNB1)-negative colorectal cancer, but are not associated with CTNNB1-positive cancer risk, according to a study published online Feb. 26 in Cancer Research.

To examine whether tumor CTNNB1 status influences cellular sensitivity to obesity and physical activity, Teppei Morikawa, M.D., Ph.D., from the Dana-Farber Cancer Institute in Boston, and colleagues used tissue immunohistochemistry data on nuclear CTNNB1 expression from 861 incident rectal and colon cancers identified during follow-up of 109,046 women in the Nurses' Health Study and 47,684 men in the Health Professionals Follow-up Study.

The researchers found that greater body mass index correlated with a significantly elevated risk of CTNNB1-negative cancer (multivariate hazard ratio [HR], 1.34 for 5.0 kg/m2 increment; Ptrend = 0.0001) but not with the risk of CTNNB1-positive cancer (multivariate HR, 1.07 for 5.0 kg/m2 increment; Ptrend = 0.36). There was a significantly lower risk of CTNNB1-negative cancer with higher physical activity levels (multivariate HR, 0.93 for 10 metabolic equivalent task [MET]-hours/week increment; Ptrend = 0.044) but no association with CTNNB1-positive cancer risk (multivariate HR, 0.98 for 10 MET-hours/week increment; Ptrend = 0.60).

"These data suggest that energy balance status exerts its effect in a specific carcinogenic pathway that is less likely dependent on WNT/ CTNNB1 activation," write the authors. "In the future, we may be able to identify individuals who are susceptible to the development of CTNNB1-negative tumors, and lifestyle preventive measures can be taken."

Abstract
Full Text (subscription or payment may be required)

This article originally appeared here.
Share this article:

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Community Poll

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs

More in Gastrointestinal Cancers

After Colorectal Cancer Surgery, Risk-Adjusted Readmission Rates Similar

After Colorectal Cancer Surgery, Risk-Adjusted Readmission Rates Similar

Little variation in hospital readmission rates in colorectal cancer surgery after adjustment for patient characteristics, comorbidities.

Biomarker May Predict Response to Sorafenib in Patients with Liver Cancer

Biomarker May Predict Response to Sorafenib in Patients ...

Patients with liver cancer whose tumors cells have less differentiated mesenchymal phenotype and CD44 are less likely to respond to sorafenib.

FOLFOXIRI with Bevacizumab Aids Metastatic Colorectal Cancer Outcomes

FOLFOXIRI with Bevacizumab Aids Metastatic Colorectal Cancer Outcomes

Findings show benefits compared with FOLFIRI for patients with untreated metastatic colorectal cancer disease.